These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 14508366

  • 1. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se?
    Birkeland SA, Hamilton-Dutoit S.
    Transplantation; 2003 Sep 27; 76(6):984-8. PubMed ID: 14508366
    [Abstract] [Full Text] [Related]

  • 2. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients.
    Younes BS, McDiarmid SV, Martin MG, Vargas JH, Goss JA, Busuttil RW, Ament ME.
    Transplantation; 2000 Jul 15; 70(1):94-9. PubMed ID: 10919581
    [Abstract] [Full Text] [Related]

  • 3. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S, Renner C, Hammer M, Abdul-Khaliq H, Lehmkuhl HB, Berger F, Hetzer R, Reinke P.
    J Heart Lung Transplant; 2008 Jan 15; 27(1):100-5. PubMed ID: 18187094
    [Abstract] [Full Text] [Related]

  • 4. Long-term follow-up of kidney transplant patients with posttransplant lymphoproliferative disorder: duration of posttransplant lymphoproliferative disorder-induced operational graft tolerance, interleukin-18 course, and results of retransplantation.
    Birkeland SA, Hamilton-Dutoit S, Bendtzen K.
    Transplantation; 2003 Jul 15; 76(1):153-8. PubMed ID: 12865802
    [Abstract] [Full Text] [Related]

  • 5. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation.
    Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW.
    Transplantation; 2003 Nov 15; 76(9):1289-93. PubMed ID: 14627905
    [Abstract] [Full Text] [Related]

  • 6. [Diffuse lymphoproliferative disease after renal transplantation and its relation with Epstein-Barr virus. Experience at one center].
    Franco A, Jiménez L, Aranda I, Alvarez L, González M, Rocamora N, Olivares J.
    Nefrologia; 2002 Nov 15; 22(5):463-9. PubMed ID: 12497748
    [Abstract] [Full Text] [Related]

  • 7. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment.
    Guthery SL, Heubi JE, Bucuvalas JC, Gross TG, Ryckman FC, Alonso MH, Balistreri WF, Hornung RW.
    Transplantation; 2003 Apr 15; 75(7):987-93. PubMed ID: 12698085
    [Abstract] [Full Text] [Related]

  • 8. Posttransplant lymphoproliferative disorders in transplant recipients.
    Timurağaoğlu A, Uğur-Bilgin A, Colak D, Tuncer M, Gölbaşi I, Hazar V, Kiliçarsłan B, Undar L, Demirbaş A.
    Transplant Proc; 2006 Mar 15; 38(2):641-5. PubMed ID: 16549195
    [Abstract] [Full Text] [Related]

  • 9. Analysis of risk factors for the development of posttransplant lymphoprolipherative disorder among 119 children who received primary intestinal transplants at a single center.
    Quintini C, Kato T, Gaynor JJ, Ueno T, Selvaggi G, Gordon P, McLaughlin G, Tompson J, Ruiz P, Tzakis A.
    Transplant Proc; 2006 Mar 15; 38(6):1755-8. PubMed ID: 16908272
    [Abstract] [Full Text] [Related]

  • 10. Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: use of aciclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol.
    Birkeland SA, Andersen HK, Hamilton-Dutoit SJ.
    Transplantation; 1999 May 15; 67(9):1209-14. PubMed ID: 10342310
    [Abstract] [Full Text] [Related]

  • 11. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation.
    Sundin M, Le Blanc K, Ringdén O, Barkholt L, Omazic B, Lergin C, Levitsky V, Remberger M.
    Haematologica; 2006 Aug 15; 91(8):1059-67. PubMed ID: 16885046
    [Abstract] [Full Text] [Related]

  • 12. Post-transplant lymphoproliferative disorders after live donor renal transplantation.
    Jain M, Badwal S, Pandey R, Srivastava A, Sharma RK, Gupta RK.
    Clin Transplant; 2005 Oct 15; 19(5):668-73. PubMed ID: 16146560
    [Abstract] [Full Text] [Related]

  • 13. OKT3 and ganciclovir treatments are possibly related to the presence of Epstein-Barr virus in serum after liver transplantation.
    Barkholt L, Linde A, Falk KI.
    Transpl Int; 2005 Jul 15; 18(7):835-43. PubMed ID: 15948864
    [Abstract] [Full Text] [Related]

  • 14. Post-transplant lymphoproliferative disorder following pediatric heart transplantation.
    Mendoza F, Kunitake H, Laks H, Odim J.
    Pediatr Transplant; 2006 Feb 15; 10(1):60-6. PubMed ID: 16499589
    [Abstract] [Full Text] [Related]

  • 15. Increased risk for posttransplant lymphoproliferative disease in recipients of liver transplants with hepatitis C.
    McLaughlin K, Wajstaub S, Marotta P, Adams P, Grant DR, Wall WJ, Jevnikar AM, Rizkalla KS.
    Liver Transpl; 2000 Sep 15; 6(5):570-4. PubMed ID: 10980055
    [Abstract] [Full Text] [Related]

  • 16. Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoroliferative disorder in adult renal allograft recipients.
    Shahinian VB, Muirhead N, Jevnikar AM, Leckie SH, Khakhar AK, Luke PP, Rizkalla KS, Hollomby DJ, House AA.
    Transplantation; 2003 Mar 27; 75(6):851-6. PubMed ID: 12660514
    [Abstract] [Full Text] [Related]

  • 17. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.
    Schubert S, Abdul-Khaliq H, Lehmkuhl HB, Yegitbasi M, Reinke P, Kebelmann-Betzig C, Hauptmann K, Gross-Wieltsch U, Hetzer R, Berger F.
    Pediatr Transplant; 2009 Feb 27; 13(1):54-62. PubMed ID: 18518912
    [Abstract] [Full Text] [Related]

  • 18. Epstein-Barr virus load in whole blood is associated with immunosuppression, but not with post-transplant lymphoproliferative disease in stable adult heart transplant patients.
    Doesch AO, Konstandin M, Celik S, Kristen A, Frankenstein L, Sack FU, Schnabel P, Schnitzler P, Katus HA, Dengler TJ.
    Transpl Int; 2008 Oct 27; 21(10):963-71. PubMed ID: 18564989
    [Abstract] [Full Text] [Related]

  • 19. Posttransplant lymphoproliferative disorder after umbilical cord blood transplantation in children.
    Gong JZ, Bayerl MG, Sandhaus LM, Sebastian S, Rehder CW, Routbort M, Lagoo AS, Szabolcs P, Chiu J, Comito M, Buckley PJ.
    Am J Surg Pathol; 2006 Mar 27; 30(3):328-36. PubMed ID: 16538052
    [Abstract] [Full Text] [Related]

  • 20. Acute renal allograft rejection in patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder.
    Purighalla R, Shapiro R, Jordan ML, Scantlebury VP, Gritsch HA, Vivas C, Randhawa PS.
    Clin Transplant; 1997 Dec 27; 11(6):574-6. PubMed ID: 9408687
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.